Academic Journal
View in EDS
HTML Full Text

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.

Bibliographic Details
Title: An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Authors: Cavalieri, Stefano1,2 (AUTHOR) stefano.cavalieri@istitutotumori.mi.it, Serafini, Mara Serena3 (AUTHOR), Carenzo, Andrea3 (AUTHOR), Canevari, Silvana4 (AUTHOR), Lenoci, Deborah3 (AUTHOR), Pistore, Federico1 (AUTHOR), Miceli, Rosalba5 (AUTHOR), Vecchio, Stefania6 (AUTHOR), Ferrari, Daris7 (AUTHOR), Moro, Cecilia8 (AUTHOR), Sponghini, Andrea9 (AUTHOR), Caldara, Alessia10 (AUTHOR), Rocca, Maria Cossu11 (AUTHOR), Secondino, Simona12 (AUTHOR), Moretti, Gabriella13 (AUTHOR), Denaro, Nerina14 (AUTHOR), Caponigro, Francesco15 (AUTHOR), Vaccher, Emanuela16 (AUTHOR), Rinaldi, Gaetana17 (AUTHOR), Ferraù, Francesco18 (AUTHOR)
Source: Cells (2073-4409). Oct2022, Vol. 11 Issue 19, p3176. 11p.
Subject Terms: *CETUXIMAB, *HEAD & neck cancer, *EPIDERMAL growth factor receptors, *PROGRESSION-free survival, *CANCER chemotherapy, *PROGNOSIS
Abstract: Epidermal growth factor receptor (EGFR) pathway has been shown to play a crucial role in several inflammatory conditions and host immune-inflammation status is related to tumor prognosis. This study aims to evaluate the prognostic significance of a four-gene inflammatory signature in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with the EGFR inhibitor cetuximab plus chemotherapy. The inflammatory signature was assessed on 123 R/M HNSCC patients, enrolled in the multicenter trial B490 receiving first-line cetuximab plus platinum-based chemotherapy. The primary endpoint of the study was progression free survival (PFS), while secondary endpoints were overall survival (OS) and objective response rate (ORR). The patient population was subdivided into 3 groups according to the signature score groups. The four-genes-signature proved a significant prognostic value, resulting in a median PFS of 9.2 months in patients with high vs. 6.2 months for intermediate vs. 3.9 months for low values (p = 0.0016). The same findings were confirmed for OS, with median time of 18.4, 13.4, and 7.5 months for high, intermediate, and low values of the score, respectively (p = 0.0001). When ORR was considered, the signature was significantly higher in responders than in non-responders (p = 0.0092), reaching an area under the curve (AUC) of 0.65 (95% CI: 0.55–0.75). Our findings highlight the role of inflammation in the response to cetuximab and chemotherapy in R/M-HNSCC and may have translational implications for improving treatment selection. [ABSTRACT FROM AUTHOR]
Copyright of Cells (2073-4409) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:a9h&genre=article&issn=20734409&ISBN=&volume=11&issue=19&date=20221001&spage=3176&pages=3176-3186&title=Cells (2073-4409)&atitle=An%20Inflammatory%20Signature%20to%20Predict%20the%20Clinical%20Benefit%20of%20First-Line%20Cetuximab%20Plus%20Platinum-Based%20Chemotherapy%20in%20Recurrent%2FMetastatic%20Head%20and%20Neck%20Cancer.&aulast=Cavalieri%2C%20Stefano&id=DOI:10.3390/cells11193176
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: a9h
DbLabel: Academic Search Complete
An: 159667607
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Cavalieri%2C+Stefano%22">Cavalieri, Stefano</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<i> stefano.cavalieri@istitutotumori.mi.it</i><br /><searchLink fieldCode="AR" term="%22Serafini%2C+Mara+Serena%22">Serafini, Mara Serena</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Carenzo%2C+Andrea%22">Carenzo, Andrea</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Canevari%2C+Silvana%22">Canevari, Silvana</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lenoci%2C+Deborah%22">Lenoci, Deborah</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pistore%2C+Federico%22">Pistore, Federico</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Miceli%2C+Rosalba%22">Miceli, Rosalba</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vecchio%2C+Stefania%22">Vecchio, Stefania</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ferrari%2C+Daris%22">Ferrari, Daris</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moro%2C+Cecilia%22">Moro, Cecilia</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sponghini%2C+Andrea%22">Sponghini, Andrea</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Caldara%2C+Alessia%22">Caldara, Alessia</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rocca%2C+Maria+Cossu%22">Rocca, Maria Cossu</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Secondino%2C+Simona%22">Secondino, Simona</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moretti%2C+Gabriella%22">Moretti, Gabriella</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Denaro%2C+Nerina%22">Denaro, Nerina</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Caponigro%2C+Francesco%22">Caponigro, Francesco</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vaccher%2C+Emanuela%22">Vaccher, Emanuela</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rinaldi%2C+Gaetana%22">Rinaldi, Gaetana</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ferraù%2C+Francesco%22">Ferraù, Francesco</searchLink><relatesTo>18</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Cells+%282073-4409%29%22">Cells (2073-4409)</searchLink>. Oct2022, Vol. 11 Issue 19, p3176. 11p.
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: *<searchLink fieldCode="DE" term="%22CETUXIMAB%22">CETUXIMAB</searchLink><br />*<searchLink fieldCode="DE" term="%22HEAD+%26+neck+cancer%22">HEAD & neck cancer</searchLink><br />*<searchLink fieldCode="DE" term="%22EPIDERMAL+growth+factor+receptors%22">EPIDERMAL growth factor receptors</searchLink><br />*<searchLink fieldCode="DE" term="%22PROGRESSION-free+survival%22">PROGRESSION-free survival</searchLink><br />*<searchLink fieldCode="DE" term="%22CANCER+chemotherapy%22">CANCER chemotherapy</searchLink><br />*<searchLink fieldCode="DE" term="%22PROGNOSIS%22">PROGNOSIS</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Epidermal growth factor receptor (EGFR) pathway has been shown to play a crucial role in several inflammatory conditions and host immune-inflammation status is related to tumor prognosis. This study aims to evaluate the prognostic significance of a four-gene inflammatory signature in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with the EGFR inhibitor cetuximab plus chemotherapy. The inflammatory signature was assessed on 123 R/M HNSCC patients, enrolled in the multicenter trial B490 receiving first-line cetuximab plus platinum-based chemotherapy. The primary endpoint of the study was progression free survival (PFS), while secondary endpoints were overall survival (OS) and objective response rate (ORR). The patient population was subdivided into 3 groups according to the signature score groups. The four-genes-signature proved a significant prognostic value, resulting in a median PFS of 9.2 months in patients with high vs. 6.2 months for intermediate vs. 3.9 months for low values (p = 0.0016). The same findings were confirmed for OS, with median time of 18.4, 13.4, and 7.5 months for high, intermediate, and low values of the score, respectively (p = 0.0001). When ORR was considered, the signature was significantly higher in responders than in non-responders (p = 0.0092), reaching an area under the curve (AUC) of 0.65 (95% CI: 0.55–0.75). Our findings highlight the role of inflammation in the response to cetuximab and chemotherapy in R/M-HNSCC and may have translational implications for improving treatment selection. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Cells (2073-4409) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=a9h&AN=159667607
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/cells11193176
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 3176
    Subjects:
      – SubjectFull: CETUXIMAB
        Type: general
      – SubjectFull: HEAD & neck cancer
        Type: general
      – SubjectFull: EPIDERMAL growth factor receptors
        Type: general
      – SubjectFull: PROGRESSION-free survival
        Type: general
      – SubjectFull: CANCER chemotherapy
        Type: general
      – SubjectFull: PROGNOSIS
        Type: general
    Titles:
      – TitleFull: An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cavalieri, Stefano
      – PersonEntity:
          Name:
            NameFull: Serafini, Mara Serena
      – PersonEntity:
          Name:
            NameFull: Carenzo, Andrea
      – PersonEntity:
          Name:
            NameFull: Canevari, Silvana
      – PersonEntity:
          Name:
            NameFull: Lenoci, Deborah
      – PersonEntity:
          Name:
            NameFull: Pistore, Federico
      – PersonEntity:
          Name:
            NameFull: Miceli, Rosalba
      – PersonEntity:
          Name:
            NameFull: Vecchio, Stefania
      – PersonEntity:
          Name:
            NameFull: Ferrari, Daris
      – PersonEntity:
          Name:
            NameFull: Moro, Cecilia
      – PersonEntity:
          Name:
            NameFull: Sponghini, Andrea
      – PersonEntity:
          Name:
            NameFull: Caldara, Alessia
      – PersonEntity:
          Name:
            NameFull: Rocca, Maria Cossu
      – PersonEntity:
          Name:
            NameFull: Secondino, Simona
      – PersonEntity:
          Name:
            NameFull: Moretti, Gabriella
      – PersonEntity:
          Name:
            NameFull: Denaro, Nerina
      – PersonEntity:
          Name:
            NameFull: Caponigro, Francesco
      – PersonEntity:
          Name:
            NameFull: Vaccher, Emanuela
      – PersonEntity:
          Name:
            NameFull: Rinaldi, Gaetana
      – PersonEntity:
          Name:
            NameFull: Ferraù, Francesco
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 20734409
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 19
          Titles:
            – TitleFull: Cells (2073-4409)
              Type: main
ResultId 1